Vor Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Vor Bio completed enrollment in the Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis, with topline results on track for 1H 2027. The company is expanding the telitacicept franchise into ocular myasthenia gravis with a new Phase 3 registrational trial expected to dose first patients in 1H27, while enrollment continues in Phase 3 UPSTREAM SjD in Sjögren's disease. Vor ended Q3 2026 with $481.6 million in cash and investments, projected to fund operations into early 2029.
Key figures
- Net loss
- 86700000
- Ga expense
- 23900000
- Rd expense
- 34500000
- Cash runway
- into early 2029
- Mse 48 week
- 42.1%
- Teligan egfr slope
- -0.6 vs -5.7 mL/min/1.73 m2/year (p<0.001)
- Net loss prior year
- 812700000
- Cash and investments
- 481600000
- Ga expense prior year
- 14000000
- Rd expense prior year
- 14100000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.